首页> 外国专利> NOURIN MOLECULAR BIOMARKERS DIAGNOSE ANGINA PATIENTS WITH NEGATIVE TROPONIN

NOURIN MOLECULAR BIOMARKERS DIAGNOSE ANGINA PATIENTS WITH NEGATIVE TROPONIN

机译:Nourin分子生物标志物诊断肌钙蛋白阴性的心绞痛患者

摘要

The present invention provides a molecular network, devices, and assays for early diagnosis of angina patients experiencing acute chest pain with negative Troponin, and it reflects on disease progression and severity. The invention also allows for the diagnosis of angina in suspected patients with history of chest pain; differentiates between angina patients and acute myocardial infarction; as well as diagnose coronary artery disease patients from other non-cardiac and healthy individuals. The present invention indicates that the downregulation of Nourin IncCTB9H12.4 in coronary artery disease patients compared to non-cardiac and healthy controls, is significantly associated with upregulation of miR_106b and miR_137 resulting in overexpression of mRNA ANAPC11 and mRNA FTLH-17; respectively. Therefore, the invention provides a novel non-invasive good positive test to diagnose angina patients which also, has a good negative test to exclude chest pain non-angina patients and healthy individuals.
机译:本发明提供了分子网络,设备和测定法,用于早期诊断患有肌钙蛋白阴性的急性胸痛的心绞痛患者,它反映了疾病的进展和严重程度。本发明还允许在具有胸痛史的疑似患者中诊断心绞痛。区分心绞痛患者和急性心肌梗塞;以及诊断其他非心脏和健康个体的冠心病患者。本发明表明与非心脏和健康对照相比,冠心病患者中Nurin IncCTB9H12.4的下调与miR_106b和miR_137的上调显着相关,导致mRNA ANAPC11和mRNA FTLH-17的过表达。分别。因此,本发明提供了用于诊断心绞痛患者的新颖的非侵入性良好阳性试验,其还具有良好的阴性试验以排除胸痛非心绞痛患者和健康个体。

著录项

  • 公开/公告号US2020109454A1

    专利类型

  • 公开/公告日2020-04-09

    原文格式PDF

  • 申请/专利权人 NOUR HEART INC.;

    申请/专利号US201916719723

  • 发明设计人 SALWA AHMED ELGEBALY;

    申请日2019-12-18

  • 分类号C12Q1/6883;G16B20/20;C12Q1/686;G16H10/60;G16H10/40;G16H50/70;G16H50/50;G16H50/20;G16H50/30;G16H20/10;

  • 国家 US

  • 入库时间 2022-08-21 11:19:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号